Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares.

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Paolo Zanetti Formation: 3 - 4 - 1 - 2 Manager: Kosta Runjaic ...

Verona Pharma plc (NASDAQ:VRNA) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Verona Pharma plc, a clinical stage biopharmaceutical ...

Verona Pharma operates in a competitive COPD market, but Ohtuvayre’s differentiated mechanism of action and competitive pricing strategy position it well against established players. The product ...

Verona Pharma plc (NASDAQ:VRNA) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Verona Pharma plc, a clinical stage ...